Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
Albert Oriol*, Roman Hájek, Ivan Spicka, Irwindeep Sandhu, Yael C. Cohen, Moshe E. Gatt, José Mariz, Michele Cavo, Jesús Berdeja, Kexin Jin, Merav Bar, Prianka Das, Ross La Motte-Mohs, Yu Wang, Deepak Perumal, Luciano J. Costa
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study'. Together they form a unique fingerprint.